HC Wainwright Has Bearish Forecast for RVMD Q3 Earnings

Revolution Medicines, Inc. (NASDAQ:RVMD) – Stock analysts at HC Wainwright reduced their Q3 2026 earnings per share estimates for shares of Revolution Medicines in a report issued on Thursday, August 27th. HC Wainwright analyst R. Burns now anticipates that the company will post earnings per share of ($2.42) for the quarter, down from their prior estimate of ($2.07). HC Wainwright currently has a “Buy” rating and a $280.00 price target on the stock. The consensus estimate for Revolution Medicines’ current full-year earnings is ($8.85) per share. HC Wainwright also issued estimates for Revolution Medicines’ Q4 2026 earnings at ($2.23) EPS and FY2026 earnings at ($9.20) EPS.

A number of other equities research analysts have also weighed in on RVMD. Piper Sandler lifted their price objective on shares of Revolution Medicines to $172.00 and gave the company an “overweight” rating in a report on Thursday, May 7th. TD Cowen raised shares of Revolution Medicines to a “strong-buy” rating in a research report on Monday, August 24th. Royal Bank Of Canada lifted their price target on shares of Revolution Medicines from $203.00 to $251.00 and gave the company an “outperform” rating in a research note on Thursday. Mizuho boosted their price target on Revolution Medicines from $185.00 to $215.00 and gave the company an “outperform” rating in a report on Monday, July 6th. Finally, Needham & Company LLC increased their price objective on Revolution Medicines from $240.00 to $275.00 and gave the stock a “buy” rating in a research note on Monday. Two research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Revolution Medicines has an average rating of “Moderate Buy” and a consensus target price of $200.74.

Revolution Medicines Trading Down 1.1%

NASDAQ RVMD opened at $205.57 on Monday. The stock has a market cap of $44.06 billion, a PE ratio of -23.31 and a beta of 1.39. Revolution Medicines has a 12 month low of $37.56 and a 12 month high of $224.31. The company’s 50-day moving average price is $194.12 and its 200-day moving average price is $149.73. The company has a current ratio of 11.38, a quick ratio of 11.38 and a debt-to-equity ratio of 0.40.

Revolution Medicines (NASDAQ:RVMD) last released its earnings results on Wednesday, August 5th. The company reported ($3.06) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.04) by ($1.02). During the same period last year, the firm posted ($1.31) earnings per share.

Insider Buying and Selling at Revolution Medicines

In other news, COO Margaret A. Horn sold 60,400 shares of the company’s stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $160.17, for a total value of $9,674,268.00. Following the completion of the sale, the chief operating officer owned 158,222 shares of the company’s stock, valued at approximately $25,342,417.74. This represents a 27.63% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Sushil Patel sold 5,580 shares of the stock in a transaction that occurred on Monday, June 29th. The shares were sold at an average price of $187.99, for a total transaction of $1,048,984.20. Following the transaction, the director owned 21,656 shares in the company, valued at approximately $4,071,111.44. This represents a 20.49% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 212,497 shares of company stock worth $38,206,486. 7.60% of the stock is currently owned by company insiders.

Institutional Trading of Revolution Medicines

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Contravisory Investment Management Inc. purchased a new stake in shares of Revolution Medicines during the 2nd quarter worth $32,000. Global Retirement Partners LLC grew its stake in Revolution Medicines by 1,002.8% in the fourth quarter. Global Retirement Partners LLC now owns 397 shares of the company’s stock valued at $32,000 after purchasing an additional 361 shares during the last quarter. Johnson Financial Group Inc. purchased a new position in Revolution Medicines in the second quarter valued at about $37,000. Arax Advisory Partners bought a new position in Revolution Medicines in the fourth quarter worth about $38,000. Finally, Silvant Capital Management LLC bought a new position in Revolution Medicines in the second quarter worth about $41,000. Institutional investors own 94.34% of the company’s stock.

About Revolution Medicines

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.